Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00824993 · ClinicalTrials.gov registry record · Phase 3
Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 78
- Enrollment target
NCT00824993: Completed Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00824993 is a Phase 3 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 78 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00824993, a Phase 3 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 78 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to see if ibandronate can help to slow the rate of bone loss that may occur in patients who have received a bone marrow transplant for blood cancer. This study plans to address the following hypotheses: 1. The addition of Ibandronate initiated immediately after the transplantation will prevent bone loss in patients undergoing allogenic bone marrow transplantation (BMT) with underlying hematologic malignancies or hematologic disorders. 2. BMT patients who require prolonged steroid and other immunosuppressive treatment for Graft versus Host Diseases(GVHD) have a higher rate of bone loss, which can be prevented or attenuated by Ibandronate. Specific objectives to test these hypotheses are: 1. Primary Objective: 1\. To prospectively compare the bone mineral density changes of lumbar spine, femoral neck and total hip between patients randomly assigned to ibandronate and control group over 12 months post bone marrow transplantation at the University of Texas MD Anderson Cancer Center. 2. Secondary Objectives: 1. To measure and compare the accumulated level of steroid used in both treatment and control groups. 2. To collect and compare the level of serum C-terminal telopeptide (CTX) in both treatment and control groups to monitor the bone turnover rate for the duration of the study. 3. To conduct a cost-effectiveness analysis of participating patients for both outcomes on bone mineral density (measured data) and skeletal-related events (modeled data). 4. To record incidence of bone fractures and the graft rate in both treatment and control groups.
Interventions
- DRUG Ibandronate
- DRUG Vitamin Supplements
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2008-12-09 |
| Est. Completion | 2017-04-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00824993
The ClinicalTrials.gov registry entry for NCT00824993 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ibandronate is the first listed.
NCT00824993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00824993 about?
NCT00824993 is a clinical study titled "Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients". The goal of this clinical research study is to see if ibandronate can help to slow the rate of bone loss that may occur in patients who have received a bone marrow transplant for blood cancer. This study plans to address the following hypotheses: 1. The addition of Ibandronate initiated immediatel...
What is the current status of trial NCT00824993?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 78 participants. The study started on 2008-12-09. Estimated completion is 2017-04-07.
What interventions are being tested in trial NCT00824993?
The interventions under investigation include: Ibandronate (DRUG), Vitamin Supplements (DRUG).
Who is sponsoring clinical trial NCT00824993?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.